drugset / Trial / NCT00559962

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962

Phase 2 Completed 260 enrolled Aegerion Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy

Timeline

Start
2007-10
Primary completion
2008-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 20 mg
Comparator Ezetimibe Unknown 10 mg
Comparator Fenofibrate Small molecule 145 mg
Comparator lomitapide Small molecule 2.5 mg
Comparator lomitapide Small molecule 5 mg
Comparator lomitapide Small molecule 7.5 mg
Comparator lomitapide Small molecule 10 mg

Indications